Antitubercular agents,Isoniazid,Rifampicin,Pyrazinamide,Oxidative stress,Complementary therapies," /> Antitubercular agents,Isoniazid,Rifampicin,Pyrazinamide,Oxidative stress,Complementary therapies,"/> Clinical and experimental research in antituberculosis drug-induced hepatotoxicity: A review
Search JIM Advanced Search

Journal of Integrative Medicine ›› 2017, Vol. 15 ›› Issue (1): 27-36.doi: 10.1016/S2095-4964(17)60319-4

• Review • Previous Articles     Next Articles

Clinical and experimental research in antituberculosis drug-induced hepatotoxicity: A review

Udhaya Lavinya Baskaran, Evan Prince Sabina   

  1. School of Biosciences and Technology, VIT University, Vellore-632014, Tamilnadu, India
  • Received:2016-06-30 Accepted:2016-09-27 Online:2017-01-15 Published:2017-01-15
  • Contact: Evan Prince Sabina; E-mail:

Drug-induced liver injury is the common adverse effect seen in patients receiving antituberculosis drugs (ATDs). There are several risk factors associated with the development of hepatotoxicity in such patients. Though there have been appreciable efforts taken by carrying out studies investigating the efficacy of several natural and synthetic compounds in minimising this effect, the only choice available for clinicians is withdrawal of drugs. This review would give a precise idea of ATD-induced hepatotoxicity, its underlying mechanisms and alternative therapies for the same.

Key words: Antitubercular agents, Isoniazid, Rifampicin, Pyrazinamide, Oxidative stress, Complementary therapies

1 Sulkowski MS, Thomas DL, Chaisson RE, Moore RD.Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.JAMA. 2000; 283(1): 74-80.
2 De Lazzari E, León A, Arnaiz JA, Martinez E, Knobel H, Negredo E, Clotet B, Montaner J, Storfer S, Asenjo MA, Mallolas J, Miró JM, Gatell JM.Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts.HIV Med. 2008; 9(4): 221-226.
3 O’Donohue J, Oien KA, Donaldson P, Underhill J, Clare M, MacSween RN, Mills PR. Co-amoxiclav jaundice: clinical and histological features and HLA class II association.Gut. 2000; 47(5): 717-720.
4 Larrey D, Vial T, Micaleff A, Babany G, Morichau- Beauchant M, Michel H, Benhamou JP.Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases.Gut. 1992; 33(3): 368-371.
5 Kaplowitz N.Idiosyncratic drug hepatotoxicity.Nat Rev Drug Discov. 2005; 4: 489-499.
6 Echevarria K, Datta P, Cadena J, Lewis JS 2nd. Severe myopathy and possible hepatotoxicity related to daptomycin.J Antimicrob Chemother. 2005; 55(4): 599-600.
7 Pawlowski A, Jansson M, Sköd M, Rottenberg ME, Källenius G.Tuberculosis and HIV co-infection.PLoS Pathog. 2012; 8(2): e1002464.
8 Venkatesh KK, Swaminathan S, Andrews JR, Mayer KH.Tuberculosis and HIV co-infection: screening and treatment strategies.Drugs. 2011; 71(9): 1133-1152.
9 Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C.The growing burden of tuberculosis: global trends and interactions with the HIV epidemic.Arch Intern Med. 2003; 163(9): 1009-1021.
10 Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, Hoffner S, Rieder HL, Binkin N, Dye C, Williams R, Raviglione MC.Global trends in resistance to antituberculosis drugs. World Health Organization- International Union against Tuberculosis and Lung Disease Working Group on antituberculosis drug resistance surveillance.N Engl J Med. 2001; 344(17): 1294-1303.
11 Metushi IG, Cai P, Zhu X, Nakagawa T, Uetrecht JP.A fresh look at the mechanism of isoniazid-induced hepatotoxicity.Clin Pharmacol Ther. 2011; 89(6): 911-914.
12 Wen X, Wang JS, Neuvonen PJ, Backman JT.Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.Eur J Clin Pharmacol. 2002; 57(11): 799-804.
13 Mahatthanatrakul W, Nontaput T, Ridtitid W, Wongnawa M, Sunbhanich M.Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers.J Clin Pharm Ther. 2007; 32(2): 161-167.
14 Rae JM, Johnson MD, Lippman ME, Flockhart DA.Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays.J Pharmacol Exp Ther. 2001; 299(3): 849-857.
15 Fernández-Villar A, Sopeñ B, Fernández-Villar J, Vázquez- Gallardo R, Ulloa F, Leiro V, Mosteiro M, Piñiro L.The infl uence of risk factors on the severity of antituberculosis drug-induced hepatotoxicity.Int J Tuberc Lung Dis. 2004; 8(12): 1499-1505.
16 Hosford JD, von Fricken ME, Lauzardo M, Chang M, Dai Y, Lyon JA, Shuster J, Fennelly KP. Hepatotoxicity from antituberculous therapy in the elderly: a systematic review.Tuberculosis (Edinb). 2015; 95(2): 112-122.
17 Roberts J, Tumer N.Age and diet effects on drug action.Pharmacol Ther. 1988; 37(1): 111-149.
18 Hunt CM, Westerkam WR, Stave GM.Effect of age and gender on the activity of human hepatic CYP3A.Biochem Pharmacol. 1992; 44(2): 275-283.
19 Walter-Sack I, Klotz U.Influence of diet and nutritional status on drug metabolism.Clin Pharmacokinet. 1996; 31(1): 47-64.
20 Wilkinson GR.The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans.Adv Drug Deliv Rev. 1997; 27(2-3): 129-159.
21 Bidlack WR, Smith CH.The effect of nutritional factors on hepatic drug and toxicant metabolism.J Am Diet Assoc. 1984; 84(8): 892-898.
22 Murray M.Altered CYP expression and function in response to dietary factors: potential roles in disease pathogenesis.Curr Drug Metab. 2006; 7(1): 67-81.
23 Lima Mde F, Melo HR.Hepatotoxicity induced by antituberculosis drugs among patients coinfected with HIV and tuberculosis.Cad Saude Publica. 2012; 28(4): 698-708.
24 McKoy JM, Bennett CL, Scheetz MH, Differding V, Chandler KL, Scarsi KK, Yarnold PR, Sutton S, Palella F, Johnson S, Obadina E, Raisch DW, Parada JP. Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project.Drug Saf. 2009; 32(2): 147-158.
25 Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, Wakeford C, Shaw A, Quinn J, Gish RG, Rousseau F.Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.J Infect Dis. 2005; 191(6): 825-829.
26 Breen RA, Miller RF, Gorsuch T, Smith CJ, Schwenk A, Holmes W, Ballinger J, Swaden L, Johnson MA, Cropley I, Lipman MC.Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection.Thorax. 2006; 61(9): 791-794.
27 Lauterburg BH, Velez ME.Glutathione deficiency in alcoholics: risk factor for paracetamol hepatotoxicity.Gut. 1988; 29(9): 1153-1157.
28 Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, Pitchenik AE.Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodefi ciency virus.Am J Respir Crit Care Med. 1998; 157(6 Pt 1): 1871-1876.
29 Wilke RA, Lin DW, Roden DM, Watkins PB, Flockhart D, Zineh I, Giacomini KM, Krauss RM.Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.Nat Rev Drug Discov. 2007; 6(11): 904-916.
30 Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, Chang FY, Lee SD.Polymorphism of theN-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology. 2002; 35(4): 883-889.
31 Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R, Ito M, Yamamoto Y, Ogura T, Maeda K, Komuta K, Igarashi T, Azuma J.SlowN-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicininduced hepatotoxicity. Int J Tuberc Lung Dis. 2000; 4(3): 256-261.
32 Higuchi N, Tahara N, Yanagihara K, Fukushima K, Suyama N, Inoue Y, Miyazaki Y, Kobayashi T, Yoshiura K, Niikawa N, Wen CY, Isomoto H, Shikuwa S, Omagari K, Mizuta Y, Kohno S, Tsukamoto K.NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of antituberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis. World J Gastroenterol. 2007; 13(45): 6003-6008.
33 Sheng YJ, Wu G, He HY, Chen W, Zou YS, Li Q, Zhong L, Huang YM, Deng CL.The association between CYP2E1 polymorphisms and hepatotoxicity due to antituberculosis drugs: a meta-analysis.Infect Genet Evol. 2014; 24: 34-40.
34 Brito TC, Possuelo LG, Valim ARM, Todendi PF, Ribeiro AW, Gregianini TS, Jarczewski CA, Hutz MH, Rossetti MLR, Zaha A.Polymorphisms in CYP2E1, GSTM1 and GSTT1 and antituberculosis drug-induced hepatotoxicity.An Acad Bras Cienc. 2014; 86(2): 855-865.
35 Chatterjee S, Lyle N, Mandal A, Kundu S.GSTT1 and GSTM1 gene deletions are not associ ated with hepatotoxicity caused by antitubercular drugs. J Clin Pharm Ther. 2010; 35(4): 465-470.
36 Gengiah TN, Botha JH, Soowamber D, Naidoo K, Abdool Karim SS.Low rifampicin concentrations in tuberculosis patients with HIV infection.J Infect Dev Ctries. 2014; 8(8): 987-993.
37 Song SH, Chang HE, Jun SH, Park KU, Lee JH, Lee EM, Song YH, Song J.Relationship between CES2 genetic variations and rifampicin metabolism.J Antimicrob Chemother. 2013; 68(6): 1281-1284.
38 Kim SH, Kim SH, Yoon HJ, Shin DH, Park SS, Kim YS, Park JS, Jee YK.TNF-α genetic polymorphism -308G/A and antituberculosis drug-induced hepatitis.Liver Int. 2012; 32(5): 809-814.
39 Gi guère V. Orphan nuclear receptors: from gene to function.Endocr Rev. 1999; 20(5): 689-725.
40 Moore LB, Parks DJ, Jones SA, Bledsoe RK, Consler TG, Stimmel JB, Goodwin B, Liddle C, Blanchard SG, Willson TM, Collins JL, Kliewer SA.Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands.J Biol Chem. 2000; 275(20): 15122-15127.
41 Ihunnah CA, Jiang M, Xie W.Nuclear receptor PXR, transcriptional circuits and metabolic relevance.Biochim Biophys Acta. 2011; 1812(8): 956-963.
42 Li F, Lu J, Cheng J, Wang L, Matsubara T, Csanaky IL, Klaassen CD, Gonzalez FJ, Ma X.Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid cotherapy.Nat Med. 2013; 19(4): 418-420.
43 Shehu AI, Li G, Xie W, Ma X.The pregnane X receptor in tuberculosis therapeutics.Expert Opin Drug Metab Toxicol. 2016; 12(1): 21-30.
44 Quémard A, Lacave C, Lanéelle G.Isoniazid inhibition of mycolic acid synthesis by cell extracts of sensitive and resistant strains ofMycobacterium aurum. Antimicrob Agents Chemother. 1991; 35(6): 1035-1039.
45 Singh N, Dubey S, Chinnaraj S, Golani A, Maitra A.Study ofNAT2 gene polymorphisms in an Indian population: association with plasma isoniazid concentration in a cohort of tuberculosis patients. Mol Diagn Ther. 2009; 13(1): 49-58.
46 Gröhagen-Riska C, Hellstrom PE, Fröeth B.Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis.Am Rev Respir Dis. 1978; 118(3): 461-466.
47 Sarich TC, Youssefi M, Zhou T, Adams SP, Wall RA, Wright JM.Role of hydrazine in the mechanism of isoniazid hepatotoxicity in rabbits.Arch Toxicol. 1996; 70(12): 835-840.
48 Pal R, Rana SV, Vaiphei K, Singh K.Isoniazid-rifampicin induced lipid changes in rats.Clin Chim Acta. 2008; 389(1- 2): 55-60.
49 Martin SJ, Baskaran UL, Vedi M, Sabina EP.Attenuation of anti-tuberculosis therapy induced hepatotoxicity by Spirulina fusiformis, a candidate food supplement. Toxicol Mech Methods.2014; 24(8): 584-592.
50 Baskaran UL, Sabina EP.The food supplement coenzyme Q10 and suppression of antitubercular drug-induced hepatic injury in rats: the role of antioxidant defence system, antiinflammatory cytokine IL-10.Cell Biol Toxicol. 2015; 31(4-5): 211-219.
51 Sodhi CP, Rana SV, Mehta SK, Vaiphei K, Attari S, Mehta S.Study of oxidative-stress in isoniazid-rifampicin-induced hepatic injury in young rats.Drug Chem Toxicol. 1997; 20(3): 255-269.
52 Andrade RJ, Robles M, Fernández-Castañer A, López- Ortega S, López-Vega MC, Lucena MI.Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists.World J Gastroenterol. 2007; 13(3): 329-340.
53 Berg JM, Tymoczko JL,Stryer L.Transcription is catalyzed by RNA polymerase. In: Biochemistry. 5th ed. New York: W H Freeman and Company. 2002.
54 Anderson MS, Cote J, Liu Y, Stypinski D, Auger P, Hohnstein A, Rasmussen S, Johnson-Levonas AO, Gutstein DE.Effects of rifampin, a potent inducer of drugmetabolizing enzymes and an inhibitor of OATP1B1/3 transport, on the single dose pharmacokinetics of anacetrapib.J Clin Pharmacol. 2013; 53(7): 746-752.
55 Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ.The human bile salt export pump: characterization of substrate specifi city and identifi cation of inhibitors.Gastroenterology. 2002; 123(5): 1649-1658.
56 Baciewicz AM, Self TH.Rifamp in drug interactions.Arch Intern Med. 1984; 144(8): 1667-1671.
57 Martínez E, Collazos J, Mayo J.Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions.Medicine (Baltimore). 1999; 78(6): 361-369.
58 Buergin S, Scherer K, Häusermann P, Bircher AJ.Immediate hypersensitivity to rifampicin in 3 patients: diagnostic procedures and induction of clinical tolerance. Int Arch Allergy Immunol.2006; 140(1): 20-26.
59 Papastavros T, Dolovich LR, Holbrook A, Whitehead L, Loeb M.Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis.CMAJ. 2002; 167(2): 131-136.
60 Shih TY, Pai CY, Yang P, Chang WL, Wang NC, Hu OY.A novel mechanism underlies the hepatotoxicity of pyrazinamide.Antimicrob Agents Chemother. 2013; 57(4): 1685-1690.
61 Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin: a meta-analysis.Chest. 1991; 99(2): 465-471.
62 Amin A, Hamza AA.Oxidative stress mediates druginduced hepatotoxicity in rats: a possible role of DNA fragmentation.Toxicology. 2005; 208(3): 367-375.
63 Walubo A, Smith P, Folb PI.The role of oxygen free radicals in isoniazid-induced hepatotoxicity.Methods Find Exp Clin Pharmacol. 1998; 20(8): 649-655.
64 Adebayo AJ, Adetokunbo OA, Kehinde AJ, Olamide AE, oluwatosin A. Microsomal lipid peroxidation, antioxidant enzyme activities in brain of male rats during long-term exposure to isoniazid.J Drug Metab Toxicol. 2012; 3(4): 102-110.
65 Shuhendler AJ, Pu K, Cui L, Uetrecht JP, Rao J.Real-time imaging of oxidative and nitrosative stress in the liver of live animals for drug-toxicity testing.Nat Biotechnol. 2014; 32(4): 373-380.
66 Elmorsy E, Attalla SM, Fikry E, Kocon A, Turner R, Christie D, Warren A, Nwidu LL, Carter WG. Adverse effects of antituberculosis drugs on HepG2 cell bioenergetics. Hum Exp Toxicol.2016; Epub ahead of print.
67 Ahadpour M, Eskandari MR, Mashayekhi V, H aj Mohammad Ebrahim Tehrani K, Jafarian I, Naserzadeh P, Hosseini MJ. Mitochondrial oxidative stress and dysfunction induced by isoniazid: study on isolated rat liver and brain mitochondria.Drug Chem Toxicol. 2016; 39(2): 224-232.
68 Chowdhury A, Santra A, Bhattacharjee K, Ghatak S, Saha DR, Dhali GK.Mitochondrial oxidative stress and permeability transition in isoniazid- and rifampicin-induced liver injury in mice.J Hepatol. 2006; 45(1): 117-126.
69 Portakal O, Ozkaya O, Erden Inal M, Bozan B, Koşan M, Sayek I.Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients.Clin Biochem. 2000; 33(4): 279-284.
70 Conklin KA.Coenzyme Q10 for prevention of anthracycline-induced cardiotoxicity.Integr Cancer Ther. 2005; 4(2): 110-130.
71 Ankola DD, Viswanad B, Bhardwaj V, Ramarao P, Kumar MN.Development of potent oral nanoparticulate formulation of coenzyme Q10 for treatment of hypertension: can the simple nutritional supplements be used as fi rst line therapeutic agents for prophylaxis/therapy?Eur J Pharm Biopharm. 2007; 67(2): 361-369.
72 Lockwood K, Moesgaard S, Yamamoto T, Folkers K.Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases.Biochem Biophys Res Commun. 1995; 212(1): 172-177.
73 Pal R, Rana S, Vaiphei K, Singh K.Effect of different doses of carotenoids in isoniazid-rifampicin-induced hepatotoxicity in rats.Trop Gastroenterol. 2008; 29(3): 153-159.
74 Rana SV, Pal R, Vaiphei K, Ola RP, Singh K.Hepatoprotection by carotenoids in isoniazid-rifampicininduced hepatic injury in rats.Biochem Cell Biol. 2010; 88(5): 819-834.
75 Hussain T, Gupta RK, K S, Khan MS, Hussain MD, Arif MD, Hussain A, Faiyazuddin MD, Rao CV. Evaluation of antihepatotoxic potential ofSolanum xanthocarpum fruit extract against antitubercular drugs induced hepatopathy in experimental rodents. Asian Pac J Trop Biomed. 2012; 2(6): 454-460.
76 Tasduq SA, Singh K, Satti NK, Gupta DK, Suri KA, Johri RK.Terminalia chebula (fruit) prevents liver toxicity caused by sub-chronic administration of rifampicin, isoniazid and pyrazinamide in combination. Hum Exp Toxicol. 2006; 25(3): 111-118.
77 Pari L, Kumar NA.Hepatoprotective activity ofMoringa oleifera on antitubercular drug-induced liver damage in rats. J Med Food. 2002; 5(3): 171-177.
78 Gond NY, Khadabadi SS.Hepatoprotective activity ofFicus carica leaf extract on rifampicin-induced hepatic damage in rats. Indian J Pharm Sci. 2008; 70(3): 364-366.
79 Prabakan M, Anandan R, Devaki T.Protective effect ofHemidesmus indicus against rifampicin- and isoniazidinduced hepatotoxicity in rats. Fitoterapia. 2000; 71(1): 55-59.
80 Ravi V, Patel SS, Verma NK, Datta D, Saleem TM.Hepatoprotective activity ofBombax ceiba Linn. against isoniazid- and rifampicin-induced toxicity in experimental rats. Int J Appl Res Nat Prod. 2010; 3(3): 19-26.
81 Anbarasu C, Rajkapoor B, Kalpana J.Protective effect ofPisonia aculeata on rifampicin- and isoniazid-induced hepatotoxicity in rats. Int J Phytomedicine. 2011; 3(1): 75-83.
82 Samuel AJ, Mohan S, Chellappan DK, Kalusalingam A, Ariamuthu S.Hibiscus vitifolius Linn. root extracts shows potent protective action against antitubercular drug-induced hepatotoxicity. J Ethnopharmacol. 2012; 141(1): 396-402.
83 Obogwu MB, Akindele AJ, Adeyemi OO.Hepatoprotective andin vivo antioxidant activities of the hydroethanolic leaf extract of Mucuna pruriens (Fabaceae) in antitubercular drugs and alcohol models. Chin J Nat Med. 2014; 12(4): 273-283.
84 Rao ChV, Rawat AK, Singh AP, Singh A, Verma N. Hepatoprotective potential of ethanolic extract ofZiziphus oenoplia L. Mill roots against antitubercular drugs-induced hepatotoxicity in experimental models. Asian Pac J Trop Med. 2012; 5(4): 283-288.
85 Reddy GJ, Reddy VP, Sreepavani M, Rajaram C, Kumar SN, Kanhere RS.Evaluation of hepatoprotective potential of ethanolic extract ofIxora pavetta against isoniazid- and rifampicin-induced hepatotoxicity in rats. Drug Invent Today. 2013; 5(3): 201-206.
86 Mujahid M, Siddiqui HH, Hussain A, Hussain MS.Hepatoprotective effects ofAdenanthera pavonina Linn. against antitubercular drugs-induced hepatotoxicity in rats. Pharmacogn J. 2013; 5(6): 286-290.
87 Marasani A.Hepatoprotective activity ofBauhinia Variegata against isoniazid- and rifampicin-induced toxicity in experimental rats. Int J Pharm Pharm Sci. 2014; 6(4): 177-181.
88 Parameswari SA, Chetty CM, Chandrasekhar KB.Hepatoprotective activity ofFicus religiosa leaves against isoniazid+rifampicin and paracetamol induced hepatotoxicity. Pharmacognosy Res. 2013; 5(4): 271-276.
89 Bais B, Saiju P.Ameliorative effect ofLeucas cephalotes extract on isoniazid- and rifampicin-induced hepatotoxicity. Asian Pac J Trop Biomed. 2014; 4(Suppl 2): S633-S638.
90 Dugasani SR, Saleem TSM, Sowjanya G, Gopinath C.Hepatoprotective activity of methanolic extract ofMussaenda philippica (stems) against antitubercular drugsinduced hepatotoxicity. Int J Pharmacol Res. 2014; 4(4): 199-202.
91 Adhvaryu MR, Reddy N, Parabia MH.Effects of four Indian medicinal herbs on isoniazid-, rifampicinand pyrazinamide-induced hepatic injury and immunosuppression in guinea pigs.World J Gastroenterol. 2007; 13(23): 3199-3205.
92 Jehangir A, Nagi AH, Shahzad M, Zia A.The hepatoprotective effect ofCassia fi stula (amaltas) leaves in isoniazid- and rifampicin-induced hepatotoxicity in rodents. Biomedica. 2010; 26: 25-29.
93 Balakrishnan BR, Sangameswaran B, Bhaskar VH.Effect of methanol extract ofCuscuta reflexa aerial parts on hepatotoxicity induced by antitubercular drugs in rats. Int J Appl Res Nat Prod. 2010; 3(1): 18-22.
94 Doorika P, Ananthi T.Antioxidant and hepatoprotective properties ofTerminalia arjuna bark on isoniazid-induced toxicity in albino rats. Asian J Pharm Tech. 2012; 2(1): 15-18.
95 Palanisamy N, Manian S.Protective effects ofAsparagus racemosus on oxidative damage in isoniazid-induced hepatotoxic rats: an in vivo study. Toxicol Ind Health. 2012; 28(3): 238-244.
96 Zhang ZH, Wu HH, Xue G, Guo DN, Hou YN.Naringenin inhibits the upregulation of CYP 3A4 and attenuates the cellular toxicity induced by rifampicin and isoniazid in hepatocytes.Chin Pharmacol Bull. 2009; 25(12): 1619-1622.
97 Qader GI, Aziz RS, Ahmed ZA, Abdullah ZF, Hussain S.Protective effects of quercetin against isoniazid- and rifampicin-induced hepatotoxicity in rats.Am J Pharmacol Sci. 2014; 2(3): 56-60.
98 Ambrose SS, Solairaj P, Subramoniam A.Effectiveness of ellagic acid on isoniazid-rifampicin-induced liver damage in rats.J Pharmacol Pharmacother. 2013; 4(1): 60-62.
99 Victorrajmohan C, Pradeep K, Karthikeyan S.Infl uence of silymarin administration on hepatic glutathione-conjugating enzyme system in rats treated with antitubercular drugs.Drugs R D. 2005; 6(6): 395-400.
100 Eminzade S, Uraz F, Izzettin FV.Silymarin protects liver against toxic effects of antituberculosis drugs in experimental animals.Nutr Metab (Lond). 2008; 5: 18.
101 Singh M, Sasi P, Gupta VH, Rai G, Amarapurkar DN, Wangikar PP.Protective effect of curcumin, silymarin andN-acetylcysteine on antitubercular drug-induced hepatotoxicity assessed in an in vitro model. Hum Exp Toxicol. 2012; 31(8): 788-797.
102 Shih TY, Young TH, Lee HS, Hsieh CB, Hu OY.Protective effect of methanolic extract ofAnnona squamosa Linn in isoniazid-rifampicin-induced hepatotoxicity in rats. AAPS J. 2013; 15(3): 753-762.
103 Nicoletti NF, Rodrigues-Junior V, Santos AA Jr, Leite CE, Dias AC, Batista EL Jr, Basso LA, Campos MM, Santos DS, Souto AA.Protective effects of resveratrol on hepatotoxicity induced by isoniazid and rifampicinvia SIRT1 modulation. J Nat Prod. 2014; 77(10): 2190-2195.
104 Floyd ZE, Wang ZQ, Kilroy G, Cefalu WT.Modulation of peroxisome proliferator-activated receptor γ stability and transcriptional activity in adipocytes by resveratrol.Metabolism. 2008; 57(7 Suppl 1): S32-S38.
105 Zhang G, Zhu J, Zhou Y, Wei Y, Xi L, Qin H, Rao Z, Han M, Ma Y, Wu X.Hesperidin alleviates oxidative stress and upregulates the multidrug resistance protein 2 in isoniazidand rifampicin-induced liver injury in rats.J Biochem Mol Toxicol. 2016; 30(7): 342-349.
[1] Gerli E.G. Herr, Fábio Goulart da Silva, Francisco José Cidral-Filho, Fabricia Petronilho, Lucinéia Gainski Danielski, Mariana Pereira de Souza Goldim, Afonso Shiguemi Inoue Salgado, Franciane Bobinski, Daniel Fernandes Martins, Eliane R. Winkelmann. Effects of the use of bioceramic wraps in patients with lower limb venous ulcers: A randomized double-blind placebo-controlled trial. Journal of Integrative Medicine, 2020, 18(1): 27-.
[2] Álisson de Carvalho Gonçalves, Einy Jéssika Siqueira Moreira, Guilherme Vannucchi Portari. Benfotiamine supplementation prevents oxidative stress in anterior tibialis muscle and heart. Journal of Integrative Medicine, 2019, 17(6): 423-429.
[3] Giles Gyer, Jimmy Michael, James Inklebarger, Jaya Shanker Tedla. Spinal manipulation therapy: Is it all about the brain? A current review of the neurophysiological effects of manipulation. Journal of Integrative Medicine, 2019, 17(5): 328-337.
[4] Pranay Soni, Rajesh Choudhary, Surendra H. Bodakhe. Effects of a novel isoflavonoid from the stem bark of Alstonia scholaris against fructose-induced experimental cataract. Journal of Integrative Medicine, 2019, 17(5): 374-382.
[5] Fang-yuan Wang, Jian Jia, Huan-huan Song, Cheng-ming Jia, Chang-bo Chen, Jing Ma. Icariin protects vascular endothelial cells from oxidative stress through inhibiting endoplasmic reticulum stress. Journal of Integrative Medicine, 2019, 17(3): 205-212.
[6] Lucky Legbosi Nwidu, Yibala Ibor Oboma. Telfairia occidentalis (Cucurbitaceae) pulp extract mitigates rifampicin-isoniazid-induced hepatotoxicity in an in vivo rat model of oxidative stress. Journal of Integrative Medicine, 2019, 17(1): 46-56.
[7] Richard A. Stein, Kira Schmid, Jowell Bolivar, Andrew G. Swick, Steven V. Joyal, Steven P. Hirsh . Kaempferia parviflora ethanol extract improves self-assessed sexual health in men: A pilot study. Journal of Integrative Medicine, 2018, 16(4): 249-254.
[8] Lucky Legbosi Nwidu, Raphael Ellis Teme. Hot aqueous leaf extract of Lasianthera africana (Icacinaceae) attenuates rifampicin-isoniazid-induced hepatotoxicity. Journal of Integrative Medicine, 2018, 16(4): 263-272.
[9] Katy Andrade Monteiro Zacaron, Nélia da Silva Mendes, Yuri Cotta e Silva, Giancarlo Lucchetti. Effects of laying on of hands with and without a spiritual context on pain and functionality of older women with knee osteoarthritis: Study protocol for a randomized controlled trial. Journal of Integrative Medicine, 2018, 16(2): 106-112.
[10] Shubha Singhal, Vandana Roy. Awareness, practice and views about integrating AYUSH in allopathic curriculum of allopathic doctors and interns in a tertiary care teaching hospital in New Delhi, India. Journal of Integrative Medicine, 2018, 16(2): 113-119.
[11] Giles Gyer, Jimmy Michael, James Inklebarger. Occupational hand injuries: A current review of the prevalence and proposed prevention strategies for physical therapists and similar healthcare professionals. Journal of Integrative Medicine, 2018, 16(2): 84-89.
[12] Fabiana de Almeida Andrade, Caio Fabio Schlechta Portella. Research methods in complementary and alternative medicine: An integrative review. Journal of Integrative Medicine, 2018, 16(1): 6-13.
[13] Kayode E. Adewole, Joseph O. Adebayo. Antioxidant defense system induced by cysteine-stabilized peptide fraction of aqueous extract of Morinda lucida leaf in selected tissues of Plasmodium berghei-infected mice. Journal of Integrative Medicine, 2017, 15(5): 388-397.
[14] Uduak Akpan Okon, Idorenyin Udo Umoren. Comparison of antioxidant activity of insulin, Ocimum gratissimum L., and Vernonia amygdalina L. in type 1 diabetic rat model. Journal of Integrative Medicine, 2017, 15(4): 302-309.
[15] Yadaridee Viravud, Angkana Apichartvorakit, Pramook Mutirangura, Vasana Plakornkul, Jantima Roongruangchai, Manmas Vannabhum, Tawee Laohapand, Pravit Akarasereenont. The anatomical study of the major signal points of the court-type Thai traditional massage on legs and their effects on blood flow and skin temperature. Journal of Integrative Medicine, 2017, 15(2): 142-150.
Full text



[1] Hao Li, Ming-jiang Yao, Wen-ming Zhao, Jie Guan, Lin-lin Cai, Ling Cui. A randomized, controlled, double-blind trial of Huannao Yicong capsule in senile patients with mild cognitive impairment. Journal of Chinese Integrative Medicine, 2008, 6(1): 25-31
[2] Yi-ting He, Qing-lin Zha, Jian-ping Yu, Yong Tan, Cheng Lu, Ai-ping Lv. Principal factor analysis of symptoms of rheumatoid arthritis and their correlations with efficacy of traditional Chinese medicine and Western medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 32-36
[3] Jun Cai, Hua Wang, Sheng Zhou, Bin Wu, Hua-rong Song, Zheng-rong Xuan. Effect of Sijunzi Decoction and enteral nutrition on T-cell subsets and nutritional status in patients with gastric cancer after operation: A randomized controlled trial. Journal of Chinese Integrative Medicine, 2008, 6(1): 37-40
[4] Dong Yang, Yong-ping Du, Qing Shen, Wei Chen, Yan Yu, Guang-lei Chen. Expression of alpha-smooth muscle actin in renal tubulointerstitium in patients with kidney collateral stasis. Journal of Chinese Integrative Medicine, 2008, 6(1): 41-44
[5] SUN Ming-yu, ZUO Jian, DUAN Ji-feng, HAN Jun, FAN Shi-ming, ZHANG Wei, ZHU Li-fang, YAO Ming-hui. Antitumor activities of kushen flavonoids in vivo and in vitro. Journal of Chinese Integrative Medicine, 2008, 6(1): 51-59
[6] Xi Lin, Jian-ping Liu. Tai chi for treating rheumatoid arthritis. Journal of Chinese Integrative Medicine, 2008, 6(1): 82
[7] Guo-hong Yuan, Xiao-jing Pang, He-chao Ma. Synergic effects of Danggui Buxue Decoction in reducing toxicity of cytoxan in tumor-bearing mice. Journal of Chinese Integrative Medicine, 2008, 6(1): 83-88
[8] Li Zhou, Hong-xing Zhang, Ling-guang Liu, Wen-jun Wan. Effect of electro-acupuncture at Fenglong (GV 16) on nitric oxide and endothelin in rats with hyperlipidemia. Journal of Chinese Integrative Medicine, 2008, 6(1): 89-92
[9] Jin-zhou Tian, Jing Shi, Xin-qing Zhang, Qi Bi, Xin Ma, Zhi-liang Wang, Xiao-bin Li, Shu-li Shen, Lin Li, Zhen-yun Wu, Li-yan Fang, Xiao-dong Zhao, Ying-chun Miao, Peng-wen Wang, Ying Ren, Jun-xiang Yin, Yong-yan Wang, Beijing United Study Group on MCI of the Capital Foundation of Medical Developments. Guiding principles of clinical research on mild cognitive impairment (protocol). Journal of Chinese Integrative Medicine, 2008, 6(1): 9-14
[10] Ning-qun Wang, Liang-duo Jiang, Zong-xing Li. Research progress in asthma-related quality of life. Journal of Chinese Integrative Medicine, 2008, 6(1): 93-97